Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 2

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 2
---
ed Per Share Stock Consideration is fixed at $5.7528 (the “TuHURA Share Value”) pursuant to the terms of the Merger Agreement. However, although the number of shares of TuHURA Common Stock issuable in the transaction will not fluctuate with market prices given that the TuHURA Share Value is fixed, the market value of the Merger Consideration will fluctuate with the price of TuHURA Common Stock given TuHURA Common Stock is traded on the Nasdaq Capital Market. As part of the Merger Consideration, Kineta stockholders will be entitled to payments of legacy assets not related to the VISTA program through the Disposed Asset Payment Right as Kineta has also entered into three separate agreements to sell its assets as permitted under the Merger Agreement. Kineta has entered into an Asset Purchase Agreement dated February 4, 2025, as may be amended from time to time (the “HCRX Asset Purchase Agreement”), with HCRX Investments Holdco, L.P. (“HCRX”), pursuant to which, subject to the satisfaction or

waiver of the conditions set forth in the HCRX Asset Purchase Agreement, Kineta will sell to HCRX all of Kineta’s right, title and interest in and to certain
out-licensed programs with Merck & Co., Inc. (“Merck”), Genentech, Inc. (“Genentech”) and FAIR Therapeutics, B.V. (“FAIR”) (collectively, the “Partnered
Programs”), for a purchase price of $1.00 in cash and the right to receive 72.5% or 45%, as applicable, of any milestone or royalty payments payable to Kineta pursuant to the Partnered Programs for a period not to exceed six years (the
“Partnered Programs Asset Sale”). Kineta’s subsidiary, Kineta Chronic Pain, LLC (“Kineta Chronic Pain”), has also entered into an Asset Purchase Agreement dated February 4, 2025, as may be amended from time to time (the
“Pacira Asset Purchase Agreement”), with Pacira Pharmaceuticals, Inc. (“Pacira”), pursuant to which, among other things, Kineta Chronic Pain will sell to Pacira all of its right, title and interest in and to the assets and
properties related to KCP506, Kineta’s product candidate for pain treatment for a purchase price of $450,000 (the “KCP506 Asset Sale”). Lastly, Kineta entered